eMedExpert Home > Compare Drugs > Cefuroxime (Ceftin)

• Acute Otitis Media (ear infection)
  Results of controlled clinical studies in children 3 months to 12 years of age with AOM indicate that a 10-day regimen of oral cefuroxime axetil is as effective or more effective than a 10-day regimen of oral cefaclor, oral amoxicillin, or oral amoxicillin and clavulanate potassium. In published studies, the overall clinical response rate to a 10-day regimen of oral cefuroxime axetil in pediatric patients with AOM has ranged from 62–94%.

• Bronchitis
  Cefuroxime axetil twice daily is as effective as cefixime once daily in the treatment of acute bronchitis. Cefuroxime axetil produces fewer gastrointestinal side effects, particularly diarrhea.
  
  Randomized, investigator-blind, multicenter study5 compared the efficacy and safety of 250 mg cefuroxime axetil twice daily with that of 400 mg cefixime once daily in the treatment of acute bronchitis. Patients were randomly assigned to receive 10 days of oral treatment with either 250 mg cefuroxime axetil taken twice daily or 400 mg cefixime taken once daily. Of 465 patients with acute bronchitis who were enrolled in the study, 227 received cefuroxime axetil and 238 received cefixime. Cure or improvement was achieved in 88% (130 of 148) and 91% (152 of 167) of the clinically evaluable patients who had received cefuroxime axetil or cefixime, respectively. Regarding the eradication of bacterial pathogens, a satisfactory outcome (cure or presumed cure) was obtained in 89% (47 of 53) and 91% (41 of 45) of bacteriologically evaluated patients who had received cefuroxime axetil or cefixime. Treatment with cefixime was associated with a significantly higher incidence of drug-related gastrointestinal adverse effects than was treatment with cefuroxime axetil (18% versus 10%, respectively). This difference primarily reflects a higher rate of drug-related diarrhea (15% versus 5%).

• Skin infections
  Cefuroxime axetil may be more effective than cafadroxil for the treatment of skin or skin structure infections in children.
  
  A randomized, single-blind, multicenter study8 was conducted to evaluate the safety and efficacy of cefuroxime axetil and cefadroxil suspensions for the treatment of skin or skin structure infections in 287 children. Each drug was given at a dosage of 30 mg/kg of body weight per day in two divided doses. Staphylococcus aureus and Streptococcus pyogenes, or a combination of the two, were the primary pathogens isolated from infected skin lesions. A satisfactory bacteriological response (cure or presumed cure) was obtained in 97.1 and 94.3% of children in the cefuroxime axetil and cefadroxil groups, respectively. Satisfactory clinical responses (cure or improvement) were more likely to occur in cefuroxime axetil recipients than in cefadroxil recipients (97.8 versus 90.3%). Both regimens were equally well tolerated, with side effects occurring in 7.9 and 6.1% of cefuroxime axetil and cefadroxil recipients, respectively.

• Acute Otitis Media (ear infection)
  There is evidence from a randomized study in children 6–36 months of age with acute otitis media that a 5-day regimen of cefuroxime axetil is as effective as and may be better tolerated than an 8- or 10-day regimen of amoxicillin/clavulanate2.
• Acute Otitis Media with Effusion
  Cefuroxime axetil suspension 15 mg/kg twice daily is as effective as amoxicillin/clavulanate suspension 13.3 mg/kg three times daily in the treatment of children with acute otitis media with effusion, but produces fewer gastrointestinal side effects, particularly diarrhea1.
• Bronchitis
  Cefuroxime axetil 250 mg twice daily is as effective as amoxicillin/clavulanate 500 mg three times daily in the treatment of acute bronchitis. Cefuroxime axetil produces fewer gastrointestinal adverse events, particularly diarrhea and nausea.
  
  Two independent, investigator-blinded, multicenter, randomized clinical trials3 compared the clinical and bacteriologic efficacy and safety of cefuroxime axetil and amoxicillin/clavulanate, in the treatment of patients with secondary bacterial infections of acute bronchitis (hereafter denoted acute bronchitis). Three hundred sixty patients with signs and symptoms of acute bronchitis were enrolled at 22 centers and were randomly assigned to receive 10 days of treatment with either cefuroxime axetil 250 mg twice daily (BID) (n= 177) or amoxicillin/clavulanate 500 mg three times daily (TID) (n = 183).
  A satisfactory clinical outcome (cure or improvement) was achieved in 86% (117 of 136) and 83% (130 of 157) of the patients treated with cefuroxime axetil or amoxicillin/clavulanate, respectively. With respect to the eradication of bacterial pathogens, a satisfactory outcome (cure, presumed care, or cure with colonization) was obtained in 91% (53 of 58) and 86% (60 of 70) of patients treated with cefuroxime axetil or amoxicillin/clavulanate, respectively. Treatment with amoxicillin/clavulanate was associated with a significantly higher incidence of drug-related side effects than was treatment with cefuroxime axetil (39% vs 23%), primarily reflecting a higher incidence of drug-related gastrointestinal adverse effects (37% vs 15%), particularly diarrhea and nausea. Four patients in the cefuroxime axetil group and eight patients in the amoxicillin/clavulanate group withdrew from the study because of drug-related adverse effects.
• Community-acquired pneumonia
  Cefuroxime axetil twice a day is as effective as amoxycillin/clavulanate three times a day in the treatment of outpatients with mild to moderate community-acquired pneumonia.
  
  In a multicentre, investigator-blinded clinical trial4, 162 patients with community-acquired pneumonia were randomly assigned to receive orally either cefuroxime axetil 500 mg twice a day (n = 84) or amoxycillin/clavulanate 500 mg/125 mg three times a day (n = 78) for 10 days. Cure or improvement were achieved in 100% (55 of 55) and 96% (49 of 51) of patients treated with cefuroxime axetil or amoxycillin/clavulanate, respectively. With respect to eradication of bacterial pathogens, a satisfactory outcome (cure, presumed cure or cure with colonization) was obtained in 94% (32 of 34) and 93% (37 of 40) of patients treated with cefuroxime axetil or amoxycillin/clavulanate, respectively. Both treatment regimens used in this study were well tolerated. The most common drug-related side effects were gastrointestinal, reported by 8% and 4%, respectively, of the patients in the amoxycillin/clavulanate and cefuroxime axetil groups.
• Sinusitis
  Cefuroxime axetil is as effective as amoxicillin/clavulanate in the treatment of acute bacterial sinusitis but produces fewer side effects.
  
  Multicenter study10 compared the clinical and bacteriologic efficacy of cefuroxime axetil and amoxicillin/clavulanate, in the treatment of acute bacterial maxillary sinusitis. A satisfactory clinical outcome (cure or improvement) was achieved in 85% (98 of 115) and 82% (102 of 124) of patients treated with cefuroxime axetil or amoxicillin/clavulanate, respectively. With respect to the eradication of the bacterial pathogens, a satisfactory outcome (cure or presumed cure) was obtained in 84% (31 of 37) and 87% (34 of 39) of patients treated with cefuroxime axetil or amoxicillin/clavulanate, respectively. Treatment with amoxicillin/clavulanate was associated with a significantly higher incidence of drug-related adverse effects (13% versus 3%), particularly diarrhea (8% versus 1%). Two patients in the cefuroxime axetil group and three patients in the amoxicillin/clavulanate group withdrew from the study due to adverse effects.
  

• Lyme disease (erythema migrans)
  Cefuroxime axetil and phenoxymethyl penicillin are equally effective in the treatment of children with erythema migrans. Side effects occur more frequently with cefuroxime axetil.
  
  The clinical study18 compared the efficacy and drug-related adverse effects of cefuroxime axetil or phenoxymethyl penicillin in the treatment of children with erythema migrans. Forty-six patients received cefuroxime axetil (group C) and 44, phenoxymethyl penicillin (group P). The clinical course during the post-treatment period revealed no significant differences between the two groups: the duration of erythema migrans (7.1 +/- 7.5 days in group C, 10.6 +/- 19.3 days in group P) and the appearance of minor manifestations of Lyme borreliosis (8.8% in group C, 9.1% in group P) were comparable; no major manifestations were recorded. Twelve months after antibiotic treatment all patients were free of symptoms. The patients treated with cefuroxime axetil had more drug-related adverse effects than did those treated with phenoxymethyl penicillin (26.1% versus 6.8%). "Herxheimer's reaction" at the beginning of treatment was identified more often in group C than in group P.
• Streptococcal pharyngitis (Strep Throat)
  Cefuroxime axetil is at least as effective as penicillin V in the treatment of streptococcal pharyngitis and may be more effective in preventing the carrier state19-21.
  
  The German Society for Pediatric Infectious Diseases (DGPI) undertook a large study of culture-proven tonsillopharyngitis involving several agents and included a 1 year follow-up to establish the effect on complications. In one arm of this study, cefuroxime 250 mg bid was compared with 50,000 IU penicillin V given in three divided doses. Cefuroxime axetil was more effective than oral penicillin V in eradicating group A beta-haemolytic streptococci (GABHS) at the assessment 2-4 days post-treatment (441/490 (90%) patients versus 1196/1422 (84%) patients). Clinically, the two agents were equivalent in efficacy, and carriage rates were similar (11.1% and 13.8%, respectively) in patients receiving cefuroxime axetil and penicillin V, 7-8 weeks post-treatment. One case of glomerular nephritis occurred in a patient given penicillin V. There were no post-streptococcal complications confirmed for patients treated with cefuroxime axetil. The findings confirm the previously reported efficacy of short-course (4-5 day) treatments with cefuroxime axetil and indicate that short-course treatment is comparable to the standard oral penicillin V regimen in preventing post-streptococcal sequelae.
• Recurrent Streptococcal pharyngitis (Strep Throat)
  Cefuroxime axetil is more effective than penicillin V for the treatment of recurrent tonsillopharyngitis.
  
  Comparative, randomized, investigator-blind, multicentre trial22 studied the efficacy of cefuroxime axetil compared with penicillin V for recurrent tonsillopharyngitis (group A beta-haemolytic streptococci). A total of 236 children (aged 3-12 years with a history of at least 1 episode of tonsillopharyngitis requiring antibiotic therapy during the previous 3 months) with culture-proven tonsillitis received either cefuroxime axetil suspension or penicillin V syrup. Cefuroxime axetil treatment gave a significantly higher bacteriological eradication rate and improvement in signs and symptoms rate than penicillin V. At day 2-5 post treatment the eradication rates were 99/114 (87%) for cefuroxime axetil vs 61/109 (56%) for penicillin V. The clinical cure (resolution of signs and symptoms) rates were 98/114 (86%) and 73/109 (67%) respectively. Up to 21-28 days post-treatment, 9/114 (8%) cefuroxime axetil patients and 37/109 (34%) penicillin V patients were treatment failures or had recurrence/reinfection of streptococcal tonsillopharyngitis. More than 90% of the patients who experienced bacteriological treatment failure at either the first or second follow-up had the same serotype isolated pre- and post-treatment. During the study period, 21/114 (18%) patients in the cefuroxime axetil group and 50/109 (46%) patients in the penicillin V group received additional antibiotics. No serious adverse events were noted and the mild adverse events were equally distributed among the patients in the 2 study groups: 15% for cefuroxime axetil and 14% for penicillin V.

• Exacerbations of chronic obstructive pulmonary disease
  Both azithromycin and cefuroxime are effective treatments for exacerbations in patients with chronic obstructive pulmonary disease. Azithromycin has a lower rate of side effects.
  
  A randomized study11 compared 3 days of azithromycin treatment and 10 days of cefuroxime treatment in exacerbations in patients with chronic obstructive pulmonary disease. 50 patients were treated with azithromycin and 51 with cefuroxime. The evolution of the symptoms was similar although with a trend to greater improvement in those treated with azithromycin. Functional and gasometric evolution was similar in the two schedules. Three patients treated with azithromycin required hospital admission, as did 5 treated with cefuroxime. A greater number of treatment-related side effects were observed in patients treated with cefuroxime (18%) than in those receiving azithromycin (10%), with gastrointestinal side effects being the most commonly observed.

• Sinusitis
  Cefuroxime and clarithromycin are equally effective in the treatment of acute maxillary sinusitis.
  
  A randomised, double-blind, multicentre study23 was performed to compare the efficacy and safety of cefuroxime axetil 250 mg twice daily (n = 185) and clarithromycin 250 mg twice daily (n = 185), both administered for 10 days, in the treatment of acute sinusitis. In the cefuroxime axetil group, 169/185 (91%) patients were cured/improved at post-treatment, as were 172/185 (93%) patients receiving clarithromycin and, of these, 137/169 (81%) and 143/172 (83%) maintained their response at follow-up. Follow-up radiography showed a reduction in incidence of air fluid level and/or opacification from 96% to 15% (cefuroxime axetil) and from 96% to 11% (clarithromycin), and a decrease in frequency of mucosal thickening from 58% to 28% (cefuroxime axetil) and from 56% to 29% (clarithromycin). Only 10% of patients in either group experienced adverse effects and days absent from work were comparable.

• Lyme disease
  Cefuroxime axetil appears to be equally as effective as doxycycline in the treatment of early Lyme disease and in preventing the subsequent development of late Lyme disease.
  
  A randomized, multicenter, investigator-blinded clinical trial7 was undertaken to compare the efficacies of cefuroxime axetil and doxycycline in the treatment of Lyme disease associated with erythema migrans. Patients with physician-documented erythema migrans were treated orally for 20 days with either cefuroxime axetil (500 mg twice daily), or doxycycline (100 mg three times daily). Patients were assessed as to the resolution of erythema migrans and of the signs and symptoms related to early Lyme disease as well as to the prevention of late Lyme disease. A satisfactory clinical outcome (success or improvement) was achieved in 90 of 100 (90%) patients treated with cefuroxime axetil and in 89 of 94 (95%) patients treated with doxycycline. Patients with paresthesia, arthralgia, or irritability at enrollment were at higher risk for an unsatisfactory clinical outcome at 1 month posttreatment. Of the patients with satisfactory outcomes at 1 month posttreatment who were evaluable at 1 year posttreatment, a satisfactory outcome was achieved in 62 of 65 (95%) and in 53 of 53 (100%) patients treated with cefuroxime axetil and doxycycline. 28% of patients treated with doxycycline and 17% of those treated with cefuroxime axetil had one or more drug-related adverse effects. Doxycycline was associated with more photosensitivity reactions (6% compared with 0% for patients treated with cefuroxime axetil), and cefuroxime axetil was associated with more cases of diarrhea (5% compared with 0% for patients treated with doxycycline). Jarisch-Herxheimer reactions occurred in 12% of the patients in each treatment group.

• Sinusitis
  Ciprofloxacin is as effective as cefuroxime axetil in the treatment of acute sinusitis.
  
  In randomized, double-blind clinical study12 of 453 adults valid for clinical efficacy (228 ciprofloxacin, 225 cefuroxime axetil), ciprofloxacin treatment was statistically equivalent to cefuroxime axetil at the end of treatment (87% vs. 83%) and at follow-up (91% vs. 88%). The clinical response was similar for subgroups of patients with positive cultures, including the subset with target organisms. Bacteriologic eradication at end of therapy was similar between the two groups (97% ciprofloxacin, 95% cefuroxime axetil). Both antibiotics were equally well tolerated.
• Rhinosinusitis
  Ciprofloxacin (500 mg twice a day) and cefuroxime axetil (250 mg twice a day) are equally effective in the treatment of acute rhinosinusitis.
  
  In comparative study13 clinical resolution was observed in 559 of 613 (91.2%) ciprofloxacin-treated patients and 546 of 606 (90. 1%) cefuroxime axetil-treated patients. The two regimens were statistically equivalent. There were 80 drug-related adverse events reported in the ciprofloxacin-treated patients and 81 drug-related adverse events reported in the cefuroxime-treated patients. The main adverse events were nausea (n = 18) and diarrhea (n = 7) in patients treated with ciprofloxacin and diarrhea (n = 14), nausea (n = 12), headache (n = 7), and vaginitis (n = 7) in those treated with cefuroxime.
• Gonorrhea
  Single dose cefuroxime axetil is as effective as a single dose of ciprofloxacin in the treatment of uncomplicated gonorrhea caused by penicillinase-producing Neisseria gonorrhoeae (PPNG). However cefuroxime axetil appears to be less effective than ciprofloxacin in treating urethral gonococcal infections in men, although both drugs are highly effective in treating cervical gonococcal infections in women.
  
  In a randomized, multicenter, investigator-blind trial14 a total of 832 patients (434 females and 398 males) received a single oral dose of cefuroxime axetil 1,000 mg (417 patients) or ciprofloxacin 500 mg (415 patients). Neisseria gonorrhoeae was eradicated from the cervix in 114 of 118 (97%) and 118 of 119 (99%) females treated with cefuroxime axetil and ciprofloxacin, respectively, and from the urethra in 154 of 166 (93%) and 171 of 171 (100%) male patients treated with cefuroxime axetil and ciprofloxacin, respectively. Both medications were effective in eradicating N. gonorrhoeae in females with rectal infections (cefuroxime axetil, 29 of 30 [97%]; ciprofloxacin, 25 of 25 [100%]). In small numbers of patients, cefuroxime axetil was less effective than ciprofloxacin in treating males with pharyngeal infections (eradication in 4 of 10 and in 8 of 8 patients).
  Penicillinase-producing Neisseria gonorrhoeae was eradicated from the cervix in 22 of 23 (96%) and 32 of 32 (100%) female patients treated with cefuroxime axetil and ciprofloxacin, respectively, and from the urethra in 35 of 36 (97%) and 34 of 34 (100%) male patients treated with cefuroxime axetil and ciprofloxacin, respectively. The incidences of drug-related adverse events were similar for the two study drugs.

• Acute bacterial exacerbations of chronic bronchitis (ABECB)
  Cefuroxime and levofloxacin have similar efficacy in the treatment of acute exacerbations of chronic obstructive bronchitis.
  
  The 6-month, randomised, open-label study15 evaluated the efficacy of levofloxacin (500 mg once daily for 10 days) and cefuroxime (250 mg twice daily for 10 days) in patients experiencing AECOB episodes. In the clinically evaluable per-protocol (PPc) population and the modified intent-to-treat population, the clinical cure rates at test of cure were, respectively, 94.6% for levofloxacin versus 93.8% for cefuroxime, and 94.5% for levofloxacin versus 92.2% for cefuroxime, whilst the probability that 25% of patients would relapse during follow-up was reached within 93 days for levofloxacin compared with 81 days for cefuroxime in the PPc population. A multivariate analysis revealed that only congestive heart failure and number of AECOB episodes in the previous 12 months were predictive of relapse. Safety was comparable in the two treatment groups, with possibly related treatment-emergent adverse events occurring in 5.0% and 2.9% of subjects in the levofloxacin and cefuroxime groups, respectively.
• Community-acquired pneumonia
  Levofloxacin is superior to cefuroxime axetil in the treatment of community-acquired pneumonia.
  
  A multicenter, randomized study16 compared the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
  Clinical success was higher with levofloxacin treatment (96%) compared with the ceftriaxone and/or cefuroxime axetil (90%). In patients with typical respiratory pathogens the bacteriologic eradication rates were higher with levofloxacin (98%) compared with the ceftriaxone and/or cefuroxime axetil (85%). Levofloxacin eradicated 100% of the most frequently reported respiratory pathogens (i.e., H. influenzae and S. pneumoniae) and provided a >98% clinical success rate in patients with atypical pathogens. Side effects were reported in 5.8% of patients receiving levofloxacin and in 8.5% of patients receiving ceftriaxone and/or cefuroxime axetil. Gastrointestinal and central and peripheral nervous system adverse events were the most common events reported with each treatment.
• Sinusitis
  Levofloxacin is more effective than cefuroxime for the treatment of sinusitis.
  In the study17 the treatment success rates were 97.4% for patients who received levofloxacin and 92.8% for patients who received cefuroxime. The resolution rates of bacteria were 91.6% and 80.0%, respectively.

• Urinary Tract Infections (UTI)
  Ofloxacin may be somewhat more effective than cefuroxime axetil in the treatment of urinary tract infections in women.
  
  In a multicenter study9 163 women with acute lower urinary tract infection were treated orally with either 125 mg cefuroxime axetil or 100 mg ofloxacin twice daily for three days. Both antibiotics were generally well tolerated. Four patients in the cefuroxime axetil group and two in the ofloxacin group experienced side effects. Clinical cure and improvement were registered in 56 of 66 (84.8%) and 59 of 62 (95.2%) of the evaluable patients treated with cefuroxime axetil and ofloxacin, respectively. Seven to nine days after therapy, bacteriuria (CFU < 10(3)/ml) had been eliminated in 53 of 66 (80.3%) and 57 of 64 (89.1%) of the evaluable patients receiving cefuroxime axetil and ofloxacin, respectively.
• Acute Exacerbations of Chronic Bronchitis
  Cefuroxime axetil has better efficacy and lower risk of side effects than ofloxacin.
  
  In a randomized controlled multicenter trial24 128 patients with acute exacerbations of chronic bronchitis were treated with either cefuroxime axetil 2 x 500 mg/d (n = 65) or ofloxacin 2 x 200 mg/d for 7-8 days. According to final clinical assessment, cure was achieved with cefuroxime axetil in 75%, but only in 50% with ofloxacin. The clinical efficacy of cefuroxime axetil was judged by the physicians to be more reliable than ofloxacin. The difference is statistically significant. Therapy with ofloxacin had to be terminated in 2 cases due to side effects. Altogether 4 adverse events were documented with ofloxacin.

• Sinusitis
  Moxifloxacin is as effective as cefuroxime axetil in the treatment of acute sinusitis.
  
  Prospective, multicenter, randomized, double-masked clinical trial6 compared the efficacy and safety of moxifloxacin with those of cefuroxime axetil for the treatment of community-acquired acute sinusitis. Adult patients with symptoms and radiographic evidence of acute maxillary sinusitis received a 10-day oral regimen of either moxifloxacin (400 mg once daily) or cefuroxime axetil (250 mg twice daily). Four hundred fifty-seven of the patients (223 moxifloxacin, 234 cefuroxime axetil) were included in the clinical efficacy analysis. Moxifloxacin was found to be similar in effectiveness to cefuroxime axetil at the end-of-therapy visit (90% vs. 89%). Clinical relapse at the follow-up visit was reported for only 8 patients (3 moxifloxacin, 5 cefuroxime axetil). No clinically significant differences were observed with respect to the number of patients experiencing a successful clinical response based on demographic or infection characteristics. Of the 537 patients in the intent-to-treat population, drug-related adverse events were reported in 37% of moxifloxacin-treated patients and in 26% of cefuroxime axetil-treated patients. Adverse-event profiles were comparable in the 2 treatment groups, with the exception of nausea, which was reported by 11% of moxifloxacin-treated patients compared with 4% of cefuroxime axetil-treated patients.

• Cefuroxime (Ceftin) Medical Facts

• 1. Gooch WM 3rd, Blair E, Puopolo A, Paster Z, Schwartz RH, Miller HC, Smyre HL, Giguere GC, Collins JJ. Clinical comparison of cefuroxime axetil suspension and amoxicillin/clavulanate suspension in the treatment of pediatric patients with acute otitis media with effusion. Clin Ther. 1995 Sep-Oct;17(5):838-51. PubMed
• 2. Pessey JJ, Gehanno P, Thoroddsen E, Dagan R, Leibovitz E, Machac J, Pimentel JM, Marr C, Leblanc F. Short course therapy with cefuroxime axetil for acute otitis media: results of a randomized multicenter comparison with amoxicillin/clavulanate. PubMed
• 3. Henry D, Ruoff GE, Rhudy J, Puopolo A, Drehobl M, Schoenberger J, Giguere G, Collins JJ. Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with secondary bacterial infections of acute bronchitis. Clin Ther. 1995 Sep-Oct;17(5):861-74. PubMed
• 4. Higuera F, Hidalgo H, Feris J, Giguere G, Collins JJ. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 1996 Mar;37(3):555-64. PubMed
• 5. Arthur M, McAdoo M, Guerra J, Maloney R, McCluskey D, Giguere G, Gomez G, Collins JJ. Clinical Comparison of Cefuroxime Axetil with Cefixime in the Treatment of Acute Bronchitis. Am J Ther. 1996 Sep;3(9):622-629. PubMed
• 6. Burke T, Villanueva C, Mariano H Jr, Huck W, Orchard D, Haverstock D, Heyd A, Church D. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group. Clin Ther. 1999 Oct;21(10):1664-77. PubMed
• 7. Luger SW, Paparone P, Wormser GP, Nadelman RB, Grunwaldt E, Gomez G, Wisniewski M, Collins JJ. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother. 1995 Mar;39(3):661-7. PubMed
• 8. Jacobs RF, Brown WD, Chartrand S, Darden P, Drehobl MA, Yetman R, Ossi MJ. Evaluation of cefuroxime axetil and cefadroxil suspensions for treatment of pediatric skin infections. Antimicrob Agents Chemother. 1992 Aug;36(8):1614-8. PubMed
• 9. Naber KG, Koch EM. Cefuroxime axetil versus ofloxacin for short-term therapy of acute uncomplicated lower urinary tract infections in women. Infection. 1993 Jan-Feb;21(1):34-9. PubMed
• 10. Camacho AE, Cobo R, Otte J, Spector SL, Lerner CJ, Garrison NA, Miniti A, Mydlow PK, Giguere GC, Collins JJ. Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis. Am J Med. 1992 Sep;93(3):271-6. PubMed
• 11. Alvarez Gutie'rrez FJ, Soto Campos G, del Castillo Otero D, Sa'nchez Go'mez J, Caldero'n Osuna E, Rodri'guez Becerra E, Castillo Go'mez J. A randomized comparative study of 3 days of azithromycin treatment and 10 days of cefuroxime treatment in exacerbations in patients with chronic obstructive pulmonary disease Med Clin (Barc). 1999 Jul 3;113(4):124-8. PubMed
• 12. Johnson PA, Rodriguez HP, Wazen JJ, Huck W, Shan M, Tosiello R, Heyd A, Echols RM. Ciprofloxacin versus cefuroxime axetil in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. J Otolaryngol. 1999 Feb;28(1):3-12. PubMed
• 13. Weis M, Hendrick K, Tillotson G, Gravelle K. Multicenter comparative trial of ciprofloxacin versus cefuroxime axetil in the treatment of acute rhinosinusitis in a primary care setting. Rhinosinusitis Investigation Group. Clin Ther. 1998 Sep-Oct;20(5):921-32. PubMed
• 14. Thorpe EM, Schwebke JR, Hook EW 3rd, Rompalo A, McCormack WM, Mussari KL, Giguere GC, Collins JJ. Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae strains. Antimicrob Agents Chemother. 1996 Dec;40(12):2775-80. PubMed
• 15. Petitpretz P, Chone C, Tremolieres F; Investigator Study Group. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int J Antimicrob Agents. 2007 Jul;30(1):52-9. Epub 2007 May 18. PubMed
• 16. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997 Sep;41(9):1965-72. PubMed
• 17. Li XP, Qin ZM, Zheng RH, Tan QL, Zhou YY, Zhu L, Yin AF. Comparison of the effectiveness of levofloxacin and cefuroxime for the treatment of sinusitis. PubMed
• 18. Arnez M, Radsel-Medvescek A, Pleterski-Rigler D, Ruzic'-Sabljic' E, Strle F. Comparison of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans. Wien Klin Wochenschr. 1999 Dec 10;111(22-23):916-22. PubMed
• 19. Gooch WM 3rd, Swenson E, Higbee MD, Cocchetto DM, Evans EC. Cefuroxime axetil and penicillin V compared in the treatment of group A beta-hemolytic streptococcal pharyngitis. Clin Ther. 1987;9(6):670-7. PubMed
• 20. Scholz H. Streptococcal-A tonsillopharyngitis: a 5-day course of cefuroxime axetil versus a 10-day course of penicillin V. results depending on the children's age. Chemotherapy. 2004 Apr;50(1):51-4. PubMed
• 21. Adam D, Scholz H, Helmerking M. Comparison of short-course (5 day) cefuroxime axetil with a standard 10 day oral penicillin V regimen in the treatment of tonsillopharyngitis. J Antimicrob Chemother. 2000 Feb;45 Suppl:23-30. PubMed
• 22. Holm S, Henning C, Grahn E, Lomberg H, Staley H. Is penicillin the appropriate treatment for recurrent tonsillopharyngitis? Results from a comparative randomized blind study of cefuroxime axetil and phenoxymethylpenicillin in children. The Swedish Study Group. Scand J Infect Dis. 1995;27(3):221-8. PubMed
• 23. Stefansson P, Jacovides A, Jablonicky P, Sedani S, Staley H. Cefuroxime axetil versus clarithromycin in the treatment of acute maxillary sinusitis. Rhinology. 1998 Dec;36(4):173-8. PubMed
• 24. Kleckow M. Treatment of acute exacerbations of chronic bronchitis. Multicenter, randomized comparative study of cefuroxime axetil versus ofloxacin. Fortschr Med. 1991 Jul 30;109(22):450-4. PubMed